Mammoth Biosciences

About Mammoth Biosciences

Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.

```xml <problem> Current gene editing technologies face challenges in efficient and safe in vivo delivery, limiting their therapeutic potential for many diseases. Existing diagnostic methods also lack the speed and versatility needed for rapid molecular detection in diverse settings. </problem> <solution> Mammoth Biosciences is developing CRISPR-Cas-based therapeutics utilizing novel CRISPR enzymes and editing strategies to overcome in vivo delivery challenges and enable precision gene editing. The company's protein discovery and engineering platform focuses on discovering and engineering novel CRISPR-Cas systems and editing modalities to overcome delivery limitations. Mammoth Biosciences is also creating a CRISPR-based detection platform for molecular diagnostics, enabling limitless testing possibilities. </solution> <features> - Novel CRISPR-Cas enzymes for in vivo gene editing - Protein discovery and engineering platform to overcome delivery challenges - CRISPR-based detection platform for molecular diagnostics - Focus on developing permanent cures through precision editing - Development of novel editing modalities </features> <target_audience> The primary target audience includes patients with serious diseases, researchers in gene editing and molecular diagnostics, and healthcare providers seeking advanced therapeutic and diagnostic solutions. </target_audience> ```

What does Mammoth Biosciences do?

Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.

Where is Mammoth Biosciences located?

Mammoth Biosciences is based in San Francisco, United States.

When was Mammoth Biosciences founded?

Mammoth Biosciences was founded in 2017.

How much funding has Mammoth Biosciences raised?

Mammoth Biosciences has raised 374810000.

Location
San Francisco, United States
Founded
2017
Funding
374810000
Employees
189 employees
Major Investors
Redmile Group

Find Investable Startups and Competitors

Search thousands of startups using natural language

Mammoth Biosciences

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.

mammoth.bio30K+
cb
Crunchbase
Founded 2017San Francisco, United States

Funding

$

Estimated Funding

$200M+

Major Investors

Redmile Group

Team (100+)

No team information available.

Company Description

Problem

Current gene editing technologies face challenges in efficient and safe in vivo delivery, limiting their therapeutic potential for many diseases. Existing diagnostic methods also lack the speed and versatility needed for rapid molecular detection in diverse settings.

Solution

Mammoth Biosciences is developing CRISPR-Cas-based therapeutics utilizing novel CRISPR enzymes and editing strategies to overcome in vivo delivery challenges and enable precision gene editing. The company's protein discovery and engineering platform focuses on discovering and engineering novel CRISPR-Cas systems and editing modalities to overcome delivery limitations. Mammoth Biosciences is also creating a CRISPR-based detection platform for molecular diagnostics, enabling limitless testing possibilities.

Features

Novel CRISPR-Cas enzymes for in vivo gene editing

Protein discovery and engineering platform to overcome delivery challenges

CRISPR-based detection platform for molecular diagnostics

Focus on developing permanent cures through precision editing

Development of novel editing modalities

Target Audience

The primary target audience includes patients with serious diseases, researchers in gene editing and molecular diagnostics, and healthcare providers seeking advanced therapeutic and diagnostic solutions.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.